amylase would have been the sole reason for imaging/hospital referral. At a cost of £45 per test, it may be financially and clinically helpful to have decision support tools for primary care physicians' requests.

PWE-075 BILIARY BRUSH CYTOLOGY: IS IT WORTH PURSUING? A SINGLE CENTRE EXPERIENCE

Emmanuel Selvaraj*, Ian Lei, Aniko Rendek, Elena Collantes, Caroline Hughes, Adam Bailey. Oxford University Hospitals NHS Foundation Trust, London, UK

10.1136/gutjnl-2019-BSGAbstracts.306

Introduction The diagnostic sensitivity of endoscopic retrograde cholangiopancreatography (ERCP) brush cytology is typically variable (6–64%) and reported to be precisely 41.6% in a recent meta-analysis¹. The perceived futility coupled with the emergence of endoscopic ultrasound (EUS) sampling with a higher reported sensitivity (74%), has curbed the enthusiasm to obtain brush cytology in suspected pancreaticobiliary malignancies. This study aims to investigate the diagnostic yield from biliary brush cytology following introduction of changes to practice in 2014 at a single centre tertiary hospital.

Methods All adult patients who had an index brush cytology for biliary stricture at ERCP from January 2015 to January 2018 were identified and included in this retrospective study. Electronic patient records were searched for corresponding histocytopathology data, radiology report, multidisciplinary team (MDT) meeting outcome and clinic letters. Cytological diagnosis was compared with the final outcome of malignant or benign. Patients were considered to have a malignant outcome if (i) subsequent tissue sampling or resection confirmed primary or metastatic disease or (ii) there was unequivocal radiological or clinical progression of malignant disease. Patients were considered to have a benign outcome if (i) subsequent resection was benign or (ii) clinical follow-up for a minimum of 12 months was uneventful. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy were calculated. Differences in yield between cancers were assessed using Chi-square and Fisher's exact test

Results 127 patients were included with a mean age at presentation of 69.5 years (62% male). Cytological diagnosis were as follows: malignant 50.4%, suspicious 14.2%, atypical 11.0%, negative 23.6% and non-diagnostic 0.8%. 79.5% of strictures had a malignant outcome with 53.5% pancreatic cancer, 38.6% cholangiocarcinoma, 3.0% ampullary cancer and 4.9% other. Diagnostic performance test characteristics are as follows: sensitivity 79.2%, specificity 96.2%, PPV 98.8%, NPV 54.3% and accuracy 82.7%. There was no statistically significant difference in yield between pancreatic cancer and cholangiocarcinoma ($p=0.80$). Workforce restructuring and changes to laboratory practice in histopathology department significantly contributed to our higher yield.

Conclusion Biliary brush cytology yield in our centre is higher than reported in the literature and remains a valuable tool in the diagnosis of pancreaticobiliary malignancies. Multifaceted changes in practice can produce comparable yield to EUS sampling.

REFERENCE

1. Burnett AS, Bailey J, Oliver JB, *et al.* Sensitivity of alternative testing for pancreaticobiliary cancer: a 10-y review of the literature. *J Surg Res* 2014;**190**:535–47.

Small Bowel

Orals

OWE-16 DEVELOPMENT AND CLINICAL VALIDATION OF A GENETIC RISK SCORE FOR COELIAC DISEASE

¹Seth Sharp*, ¹Samuel Jones, ⁴Robert Kimmitt, ¹Michael Weedon, ²Anne Halpin, ¹Andrew Wood, ²Seema King, ¹Robin Beaumont, ³William Hagopian, ²Justine Turner, ^{1,4}Richard Oram. ¹University of Exeter Medical School, Exeter, UK; ²University of Alberta, Edmonton, Canada; ³Pacific Northwest Research Institute, Seattle, USA; ⁴Royal Devon and Exeter NHS Foundation, Exeter, UK

10.1136/gutjnl-2019-BSGAbstracts.307

Introduction Specific HLA-DQ genes predispose to coeliac disease (CD) and HLA typing is occasionally used as a rule-out test in clinic. However, CD is polygenic and genome wide association studies (GWAS) have implicated ~40 additional genetic variants. Using single nucleotide polymorphisms (SNPs) we aimed to combine all associated variants into a genetic risk score and assess its utility as a clinical tool.

Methods We used imputation to identify SNPs strongly correlated ($r^2>0.95$) with 4 key HLA-DQ haplotypes (DQ2.5/DQ2.2/DQ7.5/DQ8) in UK Biobank. We derived HLA-DQ odds ratios from 12,041 cases and 12,228 controls (Wellcome Trust). We combined this with additional SNPs from recent GWAS to generate a coeliac genetic risk score (C-GRS).

We validated the C-GRS in a population based cohort (UK Biobank) with 1237 cases identified by hospital admission codes. We genotyped the C-GRS in 161 samples from a paediatric clinic where patients had been assessed using anti-tissue transglutaminase antibodies, biopsy and HLA typing.

Results The C-GRS consisted of 42 SNPs and was highly discriminative of CD in UKBiobank. The C-GRS was more discriminative than HLA stratification alone (ROC-AUC=0.88 [95%CI:0.87–0.89] v 0.81, $p<0.0001$) and highly discriminative in the paediatric clinic (ROC-AUC=0.82 [95%CI:0.75–0.90], $p<0.0001$).

Conclusions A C-GRS can aid in identifying incident cases of CD and is more effective than HLA typing alone. Given the low costs of SNP genotyping relative to HLA typing a C-GRS could improve the availability and utility of coeliac genetic testing in CD diagnosis and in recruitment to research studies.

OWE-18 NON-RESPONSIVE AND REFRACTORY COELIAC DISEASE: THE LARGEST UK EXPERIENCE FROM THE NHS ENGLAND NATIONAL CENTRE

¹Elisabeth MR Baggus*, ¹Anupam Rej, ^{1,2}Annalisa Schiepati, ¹Lauren J Marks, ¹Nick Trott, ¹Marios Hadjiavassiliou, ¹David S Sanders. ¹Academic Unit of Gastroenterology, Royal Hallamshire Hospital, University of Sheffield, Sheffield, UK; ²Coeliac Centre, University of Pavia, Italy

10.1136/gutjnl-2019-BSGAbstracts.308

Introduction Non-responsive coeliac disease (NRCD) is defined by persisting symptoms or laboratory abnormalities in patients with coeliac disease (CD) despite a gluten-free diet (GFD). Causes of NRCD are heterogeneous, with refractory CD (RCD) being associated with poor prognosis. The aims of this study are to identify the aetiologies for persisting symptoms in patients with NRCD referred to a national UK centre for CD, and to assess mortality rates in each group.

Methods Data on all CD patients, including those with persisting symptoms and tertiary referrals, was collected prospectively from 1998–2018. Patients were systematically investigated to establish the aetiology of their continued symptoms. They were also referred to a specialist coeliac dietitian to identify any lapses in GFD adherence or gluten cross-contamination. A repeat duodenal biopsy was performed and compared to previous biopsies where possible to check for histological remission. Colonoscopy, lactose hydrogen breath test, glucose hydrogen breath test, SeHCAT scan, CLO testing, faecal elastase, immunohistochemistry and γ -TCR clonality were performed.

Results 2,356 patients with suspected CD were seen in this time period (121 were tertiary referrals). 157 were excluded from analysis due to unconfirmed diagnosis. Of the remaining 2,199 patients with confirmed CD, 2,123 had both villous atrophy and positive IgA-EMA/TTG, and 76 had seronegative CD. Of the 2,199 patients with CD (67% female, mean age at diagnosis 42.8 ± 18.5), 292 (13%) had persisting symptoms. The leading causes for persisting symptoms in patients without RCD (73% female, mean age at diagnosis 35.7 ± 19.2) were: gluten contamination (22%), functional/irritable bowel syndrome (20%), pancreatic exocrine insufficiency (7%), reflux dysmotility (5%), and microscopic colitis (5%). Of a total of 74 patients who were identified with RCD, 56 had RCD I (71% female, mean age at CD diagnosis 41.8 ± 19.0) and 18 had RCD II (33% female, mean age at CD diagnosis 55.4 ± 13.3). After a median follow up of 40.5 months (IQR 21.8–73.3), mortality was 7% in the RCD I group, compared to 39% in the RCD II group ($p=0.019$). Higher age at diagnosis of CD is a predictor for having RCD in patients with persisting symptoms ($p<0.001$).

Conclusions This is the largest UK study of NRCD and RCD. The contemporary mortality data in RCD II remains poor. Patients with suspected RCD should be referred to the National Centre for consideration of novel therapies such as IL-15 and Stem Cell Transplant.

OWE-21 SERONEGATIVE VILLOUS ATROPHY OF UNKNOWN ORIGIN DISPLAYS DISTINCTIVE CLINICAL AND GENETIC FEATURES AND NATURAL HISTORY

^{1,2}Annalisa Schieppati*, ¹David S Sanders, ³John Goodwin, ³Tim Key, ²Paolo Giuffrida, ⁴Annalisa De Silvestri, ²Federico Biagi. ¹Academic Unit of Gastroenterology, Royal Hallamshire Hospital, Sheffield, UK, Sheffield, UK; ²Coeliac Centre, First Department of Internal Medicine, University of Pavia, Pavia, Italy; ³NHS Blood and Transplant, UK; ⁴Clinical Epidemiology, IRCCS Policlinico San Matteo, Pavia, Italy

10.1136/gutjnl-2019-BSGAbstracts.309

Introduction Seronegative villous atrophies of unknown origin (SNVA-UO) are rare and poorly defined. Aims: i) To classify SNVA-UO and study their clinical features, histology, HLA and natural history. ii) To compare genetics and survival between SNVA-UO and patients affected by coeliac disease (CD) and complicated CD.

Methods Notes of SNVA-UO patients from two referral centres were retrospectively reviewed and data on follow-up prospectively collected until 01/2019. CD and its complications and other causes of SNVA (autoimmune enteropathy, common variable immunodeficiency, olmesartan enteropathy, parasites, etc) were thoroughly excluded. Evidence of lymphoproliferative features (TCR- γ clonality on duodenal biopsies and/or past history of extra-intestinal lymphoproliferative disorders) and persistent villous atrophy (VA) during follow-up

were used as criteria to classify them, as follows. GROUP 1: SNVA without lymphoproliferative features and with spontaneous recovery of VA. GROUP 2: persistent SNVA without lymphoproliferative features. GROUP 3: persistent SNVA with lymphoproliferative features. HLA DQA1 and DQB1 allelic frequencies were compared using χ^2 test and Fisher test. Survival was analysed by means of Kaplan-Meier curves.

Results 76 patients with SNVA-UO were enrolled. 50 were included in group 1 (26F, age at diagnosis 49 ± 18 years), 14 in group 2 (7F, 43 ± 14), 12 in group 3 (5F, 52 ± 17). VA spontaneously normalized in 47 patients in group 1 after a median of 10 months, IQR 5–14.5. Histological response occurred in 4 patients in group 2 on traditional immunosuppressants. Survival analysis showed significant differences ($p<0.001$), with group 2 characterised by long-term survival (100% alive, median follow-up 61 months, IQR 50.5–97.5) and group 3 by the poorest prognosis and a mortality higher than complicated CD (58% of patients dead after a median of 11 months from diagnosis, IQR 9.5–40). Group 1 displayed a favourable outcome similar to CD. Group 2 shows a high frequency of HLA-DQB1*0301 and DQB1*06, while HLA-DQB1*02 was more frequent in group 3 and in group 1. Partial VA, dyspepsia and absence of weight loss predicted inclusion into group 1 ($p<0.001$), while hypoalbuminemia (<3.5 g/dL) inclusion into group 3 ($p<0.02$).

Conclusions For the first time we demonstrated that SNVA-UO is made by heterogeneous enteropathies with distinct clinical features, genetics and prognosis. Clinical management should be tailored accordingly.

Posters

PWE-022 THE INCIDENCE OF COELIAC DISEASE IN PATIENTS PRESENTING WITH STRESS FRACTURE TO A TERTIARY CENTRE

¹R Smith, ¹J Baldock, ²M FitzPatrick*, ¹N Jones, ¹J Newton. ¹Department of Sport and Exercise Medicine, Nuffield Orthopaedic Centre, Oxford University Hospitals NHS Foundation Trust, Oxford; ²Translational Gastroenterology Unit, University of Oxford, Oxford

10.1136/gutjnl-2019-BSGAbstracts.310

Introduction Stress fractures, fatigue-induced bone fractures caused by repetitive mechanical stress, are often multifactorial in nature and are associated with a number of metabolic bone disorders. Whilst the association between coeliac disease (CD) and osteoporosis is well-recognised, it is unclear whether an association between CD and stress fractures exists, with only rare case reports in the literature. This study aimed to examine the incidence of CD in a prospective cohort of patients presenting with stress fractures to a specialist NHS Sport and Exercise Medicine (SEM) clinic.

Methods An analysis of a prospective cohort of 100 consecutive patients with radiologically-proven stress fractures who presented to a single tertiary UK SEM clinic was performed. Electronic health records were used to examine fracture site, comorbidities, tissue transglutaminase (TTG) result, biochemistry, haematinics, dual energy x-ray absorptiometry, and endoscopy findings.

Results Seventy patients in the cohort were female (70%) and the mean age was 37 years (range 18–69). Two patients had pre-existing coeliac disease (2%). Coeliac serology was performed for 85 patients (85%), with 5 additional patients